 An injectable drug that disrupts fat cell membranes effectively reduced fat deposits under the chin called submental fat SMF in two phase III studies one of its codevelopers said Results of the two placebocontrolled studies indicated that the drug called ATX led to significant improvements in clinicianreported measurements of SMF supported by objective caliper measurements of SMF thickness according to Bayer Healthcare which is developing the drug along with Californiabased Kythera Biopharmaceuticals Patients also reported subjective impressions that their SMF  commonly known as a double chin  had been reduced with the drug Bayer said The study results involving a total of  patients in Europe were presented at a medical conference in Paris Kythera is currently performing another phase III trial in the US and Canada with topline results expected later this year Currently patients seeking to eliminate double chins usually turn to liposuction which carries some risk of adverse effects ATX is a proprietary synthetic form of sodium deoxycholate a human bile acid which helps degrade dietary fat After injection the agent acts locally to disrupt fat cells Their contents are then flushed naturally from the area In the Bayer trials the drug was administered at monthly doses of  or  mgcm  for up to  months with an additional  weeks of followup after the last dose Adverse effects were all injectionsite reactions such as pain swelling bruising induration and numbness according to Bayer Quantitative results were not released publicly Source 